Observational Study to Identify Markers Predicting Progression from Monoclonal Gammopathy or Smoldering Multiple Myeloma to Multiple Myeloma

What this Trial Is About

Researchers are studying patients with monoclonal gammopathy of unknown significance MGUS or smoldering multiple myeloma SMM who have no symptoms to understand why some develop multiple myeloma while others do not. The study aims to find markers such as age, blood protein levels, abnormal blood cell percentages, genetic information, and bone abnormalities that may help predict disease progression. This observational research is sponsored by the M.D. Anderson Cancer Center. Participants will have blood samples taken every six months for three years to collect data. Additional tests like biopsies, X-rays, PETCT scans, and MRI scans may be done based on the treating physicians judgment to monitor disease status. After three years, patients will continue to be followed up every six to twelve months to observe long-term outcomes. During the study, researchers will assess patient characteristics, clinical variables, and molecular and genetic profiles. The main outcomes include measuring the rate of progression to multiple myeloma, progression-free survival, and overall survival over three years. Patients will be monitored regularly through blood tests and imaging as needed, with ongoing follow-up after the initial three-year period to track their health status.

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma